<DOC>
	<DOCNO>NCT02142764</DOCNO>
	<brief_summary>Most expert field consider Multiple Sclerosis main auto immune disease central nervous system . In spite many work , data literature concern antigen target CD8+ T-Cell response still contradictory insufficient .</brief_summary>
	<brief_title>Preliminary Study Selective Detection CD8+ Myelin Specific T Cell Blood Multiple Sclerosis Patients</brief_title>
	<detailed_description>30 patient distribute 3 group 10 patient specific inclusion criterion participate trial : - 10 MS patient early disease onset , - 10 MS patient Natalizumab treatment - control group 10 patient neurological disease . The aim clinical trial detect CD8+ myelin specific T-Cells blood Multiple Sclerosis patient .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Group 1 : HLAA2 patient whose Multiple Sclerosis diagnose 18 year old old patient , HLAA2 Patients Multiple Sclerosis clinically isolate syndrome high risk affect Multiple Sclerosis ( criteria spatial scattering accord 2010 2005 McDonald 's criterion ) Patients without treatment treat immunomodulating therapy Patients affiliate health insurance coverage Information comprehensive agreement sign patient investigator Group 2 : HLAA2 patient hospitalize neurology department affect neuroimmunological disorder 18 year old old patient , HLAA2 patient hospitalize neurology department Patient affect Multiple Sclerosis relate inflammatory disorder Affiliated profitable subject national insurance scheme Patients affiliate health insurance coverage Information comprehensive agreement sign patient investigator Group 3 : HLAA2 Multiple Sclerosis patient treat Natalizumab therapy 18 year old old patient , HLAA2 patient relapse remitting ( RR ) MS fulfil McDonald 2005 2010 Multiple Sclerosis diagnostic criterion Patients treat Natalizumab therapy least 3 month Patients affiliate health insurance coverage Information comprehensive agreement sign patient investigator Group 1 3 : Patients undergo immunosuppressive therapy present past except Natalizumab Pregnant woman Group 2 : Patients undergo immunosuppressive therapy present past Patients affect Multiple Sclerosis relate disorder Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>CD8+ T-cells</keyword>
	<keyword>Class I Major Histocompatibility Complex ( MHC )</keyword>
	<keyword>pentamers</keyword>
</DOC>